Posatirelin
Also known as: L-6-ketopiperidine-2-carbonyl-L-leucyl-L-prolinamide, Posatirelin TRH analogue, RGH-2202
Source Posatirelin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Posatirelin is an investigational synthetic tripeptide that mimics thyrotropin‑releasing hormone (TRH). Developed as a neuroactive agent, it has been evaluated primarily for cognitive impairment in vascular dementia and Alzheimer’s disease, and for functional recovery after focal cerebral ischemia in animal models.
Mechanism of Action
Posatirelin acts as a TRH analogue, binding to TRH receptors and modulating central monoaminergic (catecholaminergic) and cholinergic neurotransmission. Pre‑clinical work also suggests neurotrophic activity that may support neuronal survival and plasticity after ischemic injury. These actions together are thought to underlie its reported improvements in memory, attention and motivation.
What the Research Shows
Clinical evidence comes from three double‑blind, multicentre trials in elderly patients with vascular dementia (1996, 1998) and one trial in late‑onset Alzheimer’s disease (1995). All reported statistically significant gains on the Gottfries‑Bråne‑Steen (GBS) rating scale and memory tests compared with placebo or active comparators, with benefits persisting after drug withdrawal in the dementia studies. A rat model of focal cerebral ischemia (1995) showed dose‑dependent amelioration of neurologic and cognitive deficits, and reduced tissue damage, with potency exceeding native TRH. A pharmacokinetic study in healthy elderly subjects (1996) demonstrated predictable absorption, no accumulation, and a modest, reversible reduction in basal TSH without other endocrine disturbances. No regulatory approval has been granted; the data are limited to studies conducted in the 1990s.
Reported Benefits
Evidence from the dementia trials suggests posatirelin can improve global cognitive function, memory, orientation and motivation in patients with vascular or degenerative dementia, with a tolerable safety profile. Animal data indicate it may aid functional recovery after cerebral ischemia and provide neuroprotection. Endocrine effects appear minimal in short‑term use.
Limitations of the Evidence
The clinical studies involve modest sample sizes, heterogeneous patient groups, and were conducted over two decades ago; no recent large‑scale trials have confirmed the findings. Endpoints were primarily rating‑scale scores, and long‑term disease‑modifying effects remain unproven. The modest TSH suppression observed warrants monitoring in longer treatments. Overall, the evidence is promising but insufficient for definitive conclusions.
Safety Considerations
Posatirelin was well tolerated in all reported trials. The incidence of adverse events was low (≈7 % in the 1998 dementia study) and no serious drug‑related events were documented. In healthy elderly subjects, short‑term dosing did not produce clinically relevant endocrine changes except a gradual decline in basal TSH, which remained within normal limits. No accumulation was observed after repeated dosing.
How It Is Administered
Investigational protocols have used daily intramuscular injections of a 10 mg/ml solution for 2–12 weeks, with an initial oral placebo run‑in phase. Intravenous and oral routes are listed as possible administration pathways, but efficacy data are limited to the intramuscular regimen.
Routes of Administration
Goals & Uses
- Treatment of disorders of consciousnessNeurologicalLow
- Analeptic / arousal stimulationNeurologicalModerate
- NeuroprotectionNeurologyLow
- Treatment of spinal muscular atrophy (SMA)NeuromuscularLow
- TSH/prolactin stimulation (diagnostic)EndocrinologicalModerate
Contraindications
- Hypersensitivity to posatirelin or TRH analoguesAllergy/ImmunologicalHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Active epilepsy / seizure disorderNeurologicalModerate
- Uncontrolled hyperthyroidismEndocrinologicalHigh
Adverse Effects
- Transient blood pressure changesCardiovascularUncommon
- Urinary urgencyGenitourinaryUncommon
- FlushingVascularCommonWarmth and redness of the skin
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- Increased TSH/prolactin levelsEndocrinologicalCommon
Drug Interactions
- Antiepileptic drugsModerate
- Thyroid hormones (T3/T4)Moderate
- Dopamine antagonists (antipsychotics)Low
Population Constraints
- Pregnant or lactating womenReproductiveRelative
- Pediatric patients (SMA context)AgeRelative
- Elderly patientsAgeRelative
- Patients with thyroid or pituitary diseaseDisease StateRelative
Regulatory Status
- European UnionInvestigationalStudied in European clinical trials (notably Italy) for neurological conditions; no marketing authorization granted.
- United StatesUnapprovedNot approved by the FDA for any indication; investigational use only.
- United KingdomUnapprovedNo approved status in the UK; remains a research compound.
Not approved by FDA, EMA, or other major regulatory agencies for any indication. Investigated in clinical trials in Europe (particularly Italy) during the 1990s–2000s for neurological indications. Currently remains an investigational/research compound.
Evidence & Sources
- Journal ArticleModeratePantoni L2004-01-01T00:00:00.000000Z
- Journal ArticleLowGasbarrini G, et al.1998-01-01T00:00:00.000000Z
- Journal ArticleModerateParnetti L, et al.1996-01-01T00:00:00.000000Z
- Journal ArticleModerateParnetti L, et al.1995-01-01T00:00:00.000000Z
- Journal ArticleLowNoda Y, et al.1995-01-01T00:00:00.000000Z
- Journal ArticleLowReboldi G, et al.1996-01-01T00:00:00.000000Z
Frequently Asked Questions
What condition has posatirelin been studied for?
Clinical trials have examined posatirelin in vascular dementia, Alzheimer’s disease, and in animal models of focal cerebral ischemia, aiming to improve cognition and functional recovery.
How is posatirelin thought to work in the brain?
As a TRH analogue, it stimulates TRH receptors, enhancing cholinergic and catecholaminergic transmission and exerting neurotrophic effects that may support neuronal survival and plasticity.
Is posatirelin approved for medical use?
No. Posatirelin remains an investigational compound; it has not received regulatory approval for any indication.
What side effects have been reported?
Adverse events were infrequent and mild; the most consistent laboratory change was a modest reduction in basal thyroid‑stimulating hormone, without overt thyroid dysfunction.
How was the drug given in the studies?
The human studies used daily intramuscular injections of a peptide solution, typically 10 mg per day, after a short oral placebo run‑in period.
What is Posatirelin?
Posatirelin is an investigational synthetic tripeptide that mimics thyrotropin‑releasing hormone (TRH). Developed as a neuroactive agent, it has been evaluated primarily for cognitive impairment in vascular dementia and Alzheimer’s disease, and for functional recovery after focal cerebral ischemia in animal models.
What is Posatirelin used for?
Posatirelin is educationally associated with: Treatment of disorders of consciousness, Analeptic / arousal stimulation, Neuroprotection, Treatment of spinal muscular atrophy (SMA), TSH/prolactin stimulation (diagnostic). Educational only — not medical advice.
How is Posatirelin administered?
Recorded routes of administration: Intravenous, Oral, Subcutaneous.
What are the potential side effects of Posatirelin?
Reported adverse effects include: Transient blood pressure changes, Urinary urgency, Flushing, Nausea, Increased TSH/prolactin levels. This list is not exhaustive — consult a qualified clinician.
Who should avoid Posatirelin?
Recorded contraindications: Hypersensitivity to posatirelin or TRH analogues, Pregnancy, Active epilepsy / seizure disorder, Uncontrolled hyperthyroidism. Consult a qualified clinician before use.